A Phase 3 interventional study of Sofosbuvir and Daklatasuvir in Hepatitis C, sponsored by Sherief Abd-Elsalam. Status unknown at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-22.
Sponsored by Sherief Abd-Elsalam · Phase 3, Interventional, and Treatment
Effect of direct-acting antiviral drugs on erectile function
Effect of direct-acting antiviral drugs on erectile function in HCV patients
Exclusion Criteria:
HCV Treatment (Sofosbuvir and Daklatasuvir)
Drug: Sofosbuvir and Daklatasuvir
supportive liver therapy
HCV Treatment (Sofosbuvir and Daklatasuvir)
Also known as: Sofaldy, mpiviropack, daklanork
Number of patients with improved erectile functions
Number of patients with improved erectile functions
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sherief Abd-Elsalam